Minsheng Securities released a research report on April 23 stating that Huaheng Biotech (688639.SH) was given a recommended rating. The main reasons for the rating include: 1) falling valine prices dragged down performance, and volume compensation continued to grow rapidly; 2) new bio-based products were successfully put into production, small varieties of amino acids were relayed, and the product matrix continued to be rich. (Mainichi Keizai Shimbun)
民生证券4月23日发布研报称，给予华恒生物（688639.SH）推荐评级。评级理由主要包括：1）缬氨酸价格下降拖累业绩表现，以量补价持续高速增长；2）生物基新产品顺利实现投产，小品种氨基酸接力，产品矩阵持续丰富。（每日经济新闻）
Minsheng Securities released a research report on April 23 stating that Huaheng Biotech (688639.SH) was given a recommended rating. The main reasons for the rating include: 1) falling valine prices dragged down performance, and volume compensation continu
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.